The safety of apatinib for the treatment of gastric cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The safety of apatinib for the treatment of gastric cancer

Published:2018-10-24 Issue:11 Volume:17 Page:1145-1150
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Geng Ruixuan¹,Song Li²,Li Jin³,Zhao Lin⁴

Affiliation:

1. International Medical Services, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China

2. Department of Gastrointestinal Surgery, China-Japan Friendship Hospital, Beijing, China

3. Department of Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China

4. Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China

Funder

the China Anti-Cancer Association

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2018.1535592

Reference34 articles.

1. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015

2. The global health burden of infection-associated cancers in the year 2002

3. Global cancer statistics, 2012

4. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Camrelizumab Combined with Apatinib for Portal Vein Tumor Thrombus in Advanced Hepatocellular Carcinoma: Two Case Reports;British Journal of Hospital Medicine;2024-08-30

2. Efficacy and safety of apatinib plus immune checkpoint inhibitors and transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma;Journal of Cancer Research and Clinical Oncology;2024-07-08

3. Apatinib combined with an anti-PD-1 agent promotes antitumour immunity in mice with ovarian cancer;2024-02-02

4. Apatinib weakens proliferation, migration, invasion, and angiogenesis of thyroid cancer cells through downregulating pyruvate kinase M2;Scientific Reports;2024-01-09

5. Targeted therapy for multiple gene mutations in multiple metastases of advanced gastric cancer: a case report;Frontiers in Oncology;2023-12-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3